期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

周疗法紫杉醇脂质体联合方案治疗胃癌的临床疗效比较 被引量：1

Comparison of Week Therapy of Paclitaxel Liposome Combined Scheme of Clinical Curative Effect of Treating Gastric Cancer
下载PDF
导出
摘要 目的重点探索周疗法紫杉醇脂质体联合方案应用于治疗胃癌患者的有效性。方法挑选的研究对象是在我院接受治疗的68例胃癌患者,观察组和对照组分别采用不同的治疗方案,对比效果。结果观察组的1年生存率、临床收益率、临床有效率明显比对照组乐观。对照组的毒副作用发生率高于观察组。结论周疗法紫杉醇脂质体联合方案应用于治疗胃癌患者切实可行,安全可靠。 ObjectiveTo explore the effectiveness of key week therapy of paclitaxel liposome combined scheme used in the treatment of patients with gastric cancer.MethodsThe research object is selected in 68 cases of gastric cancer patients in our hospital to accept the treatment, the observation group and the control group were treated by different schemes, the contrast effect.Results In the observation group, 1 years survival rate, clinical beneift rate, clinical efifciency is signiifcantly more than the control group optimistic. A control group of toxic side effect incidence was higher than that of the observation group.Conclusion Week therapy of paclitaxel liposome combined scheme is applied to the treatment of patients with gastric cancer is feasible, safe and reliable.
作者 王辉
机构地区 辽宁省瓦房店市中心医院肿瘤内科
出处 《中国继续医学教育》 2015年第6期243-244,共2页 China Continuing Medical Education
关键词 胃癌 脂质体 紫杉醇 周疗法 Gastric cancer Liposomes Paclitaxel Week therapy
分类号 R537.2 [医药卫生—内科学]
  • 相关文献

参考文献4

  • 1伍小平,庄英帜,姜浩,等.周剂量紫杉醇联合奥沙利铂二线治疗晚期胃癌23例[J].世界华人消化杂志,2014’ 3(14) : 325-326.
  • 2戚麟,高天慧,刘明月,等.紫杉醇脂质体与普通紫杉醇治疗胃癌疗效比较[J].山东医药,2014, 2(3) : 245-246.
  • 3郭晓冬,韩克起,方盛泉,张学民,潘凯,谢国群,李平.紫杉醇、顺铂和替吉奥联合化疗方案治疗晚期胃癌的疗效和安全性[J].肿瘤,2012,32(6):453-457. 被引量：28
  • 4罗素霞,陈小兵,张斌,等.紫杉醇脂质体对胃癌细胞系BGC-823增殖和侵袭力的影响[J].中国肿瘤,2013, 2(12) : 143-144.

二级参考文献14

  • 1ROTH A D, FAZIO N, STUPP R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase ii trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol, 2007, 25(22): 3217-3223.
  • 2PARK S H, LEE W K, CHUNG M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: A randomized phase Ⅱ trial in combination with infusional 5-fluorouracil[J]. Anticancer Drugs, 2006, 17(2): 225-229.
  • 3BOKU N, YAMAMOTO S, FUKUDA H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study[J]. Lancet Oncol, 2009, 10(11 ): 1063-1069.
  • 4MOCHIKI E, OHNO T, KAMIYAMA Y, et al. Phase I / Ⅱ study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer[J]. Br J Cancer, 2006, 95(12): 1642-1647.
  • 5INADA S, TOMIDOKORO T, FUKUNARI H, etal. Phase I / Ⅱ trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer[J]. Cancer Chemother Pharmacol, 2009, 63(2): 267-273.
  • 6KAWABATA R, FUJIWARA Y, DOKI Y, et al. Phase I / Ⅱ study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer[J]. Oncology, 2007, 72(3-4): 219-225.
  • 7UEDA Y, YAMAGISHI H, ICHIKAWA D, et al. Multicenter phase Ⅱ study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer[J]. Gastric Cancer, 2010, 13(3): 149-154.
  • 8O'DWYER P J, LACRETA F, HOGAN M, et al. Pharmacologic study of etoposide and cisplatin by the intraperitoneal route[J]. J Clin Pharmacol, 1991, 31(3): 253-258.
  • 9FUJIWARA Y, TAKIGUCHI S, NAKAJIMA K, et al Intraperitoneal docetaxel combined with s-1 for advanced gastric cancer with peritonea dissemination[J].J Surg Oncol, 2012, 105(1) 38-42.
  • 10ARMSTRONG D K, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. NEnglJMed, 2006, 354(1): 34-43.

共引文献27

同被引文献16

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量：1518
  • 2岳峰,贾涛.香菇多糖注射液配合紫杉醇脂质体化疗方案对晚期非小细胞肺癌疗效的观察[J].实用心脑肺血管病杂志,2010,18(12):1791-1792. 被引量：10
  • 3Santana - Davila R, Devisetty K, Szabo A, et al. Cisplatin and eto - poside versus carboplatin and pacli- taxel with concurrent radio - therapy for stage m non small - cell lung cancer: an analysis of Veterans Health Administration data [ J]. J Chn Oncol, 2015, 33 (6): 567-574.
  • 4Shimizu T, Saijo N. Common toxicity criteria: version 2. 0, an improved reference for grading the adverse re- action of cancer treatment [ J]. Nihon Rinsho, 2003, 61 (6) : 937 -942.
  • 5Qi wx, Shen Z, Lin F, et al. Paelitaxel- based versus docetaxel - based regimens in metastatic breast cancer: a systematic review and meta -analysis of ran- domized controlled trials [ J ]. Curr Med Res Opin, 2013, 99 (2): 117-125.
  • 6Wang H, Cheng G, Du Y, et al. Hypersensitivity reaction studies of a polyethoxylated castor oil - free, liposome- based alternative paclitaxel formulation [J]. Mol Med Rep, 2013, 7 (3): 947-952.
  • 7Mackey JR, Martin M, Pienkowski T, et al. Adju-vant docetaxel, doxorubicin, and cyclophosphamide in node - positive breast cancer: 10 - year follow - up of the phase 3 randomised BCIRG001 trim [J]. Lan- cet Oncol, 2013, 14 (1): 72-80.
  • 8Wang X, Zhou J, Wang Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome in- fused in non - small cell lung cancer patients with ma- lignant pleural effusions [ J ]. Eur J Cancer, 2010, 46 (8): 1474-1480.
  • 9Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non - small cell lung canc- er: a randomized phase 3 multicenter trial [ J ]. Ann Oncol, 2010, 21 (11): 2227-2232.
  • 10岳峰,贾涛.紫杉醇脂质体与紫杉醇治疗老年小细胞肺癌的疗效对比分析[J].实用心脑肺血管病杂志,2010,18(11):1583-1584. 被引量：5

引证文献1

二级引证文献5

中国继续医学教育
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部